Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.38 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 4/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2668952 | 0.72 | PDE10A (0.47) | RAB9ANPC1PDE10AALDH1A1TSHR | |
| SCHEMBL12989975 | 0.71 | PDE10A (0.45) | RAB9ANPC1PDE10AALDH1A1TSHR | |
| SCHEMBL10921639 | 0.71 | PDE10A (0.45) | RAB9ANPC1PDE10AALDH1A1TSHR | |
| SCHEMBL21389568 | 0.71 | PDE10A (0.45) | RAB9ANPC1PDE10AALDH1A1TSHR | |
| SCHEMBL9933090 | 0.71 | PDE10A (0.45) | RAB9ANPC1PDE10AALDH1A1TSHR | |
| SCHEMBL259293 | 0.71 | PDE10A (0.45) | RAB9ANPC1PDE10AALDH1A1TSHR | |
| SCHEMBL7195074 | 0.71 | PDE10A (0.45) | RAB9ANPC1PDE10AALDH1A1TSHR | |
| SCHEMBL858832 | 0.71 | MAP4K4 (0.46) | RAB9ANPC1PDE10AALDH1A1TSHR | |
| SCHEMBL9936177 | 0.70 | RAB9A (0.42) | RAB9ANPC1PDE10AALDH1A1TSHR | |
| SCHEMBL9933875 | 0.70 | RAB9A (0.45) | RAB9ANPC1PDE10AALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10426762-B2 | Inhibitors of hepatitis C virus polymerase | COCRYSTAL PHARMA, INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-20170273962-A1 | Inhibitors of Hepatitis C Virus Polymerase | COCRYSTAL PHARMA, INC. | 2017-09-28 | — | — | US | disclosed |
| US-20170273962-A1 | Inhibitors of Hepatitis C Virus Polymerase | COCRYSTAL PHARMA, INC. | 2017-09-28 | — | — | US | disclosed |
| US-9707215-B2 | Inhibitors of hepatitis C virus polymerase | COCRYSTAL, DISCOVERY, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-9707215-B2 | Inhibitors of hepatitis C virus polymerase | COCRYSTAL, DISCOVERY, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20150182514-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL PHARMA, INC. | 2015-07-02 | — | — | US | disclosed |
| US-20150182514-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL PHARMA, INC. | 2015-07-02 | — | — | US | disclosed |
| US-20140322165-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL DISCOVERY INC (US) | 2014-10-30 | — | — | US | disclosed |
| US-20140322165-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL DISCOVERY INC (US) | 2014-10-30 | — | — | US | disclosed |
| US-8771665-B2 | Inhibitors of hepatitis C virus polymerase | COCRYSTAL DISCOVERY, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20070015764-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | AGOURON PHARMACEUTICALS, INC. | 2007-01-18 | — | — | US | disclosed |
| US-7151105-B2 | Inhibitors of Hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. (US) | 2006-12-19 | — | — | US | disclosed |
| US-7148226-B2 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. (US) | 2006-12-12 | — | — | US | disclosed |
| US-20060189681-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | AGOURON PHARMACEUTICALS, INC. | 2006-08-24 | — | — | US | disclosed |
| US-20060122399-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. | 2006-06-08 | — | — | US | disclosed |
| WO-2006018725-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | PFIZER INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| EP-1597246-A2 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | PFIZER INC. (US) | 2005-11-23 | — | — | EP | disclosed |
| US-20050176701-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. | 2005-08-11 | — | — | US | disclosed |
| US-20040224960-A1 | Pharmaceutical compositions and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2004-11-11 | — | — | US | disclosed |
| WO-2004074270-A2 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | PFIZER INC. (US) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122399-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | RNASE1, GTF3C4, POLRMT | RAB9A 3785/4885NPC1 219/4885PDE10A 3125/4885 |
| US-20070015764-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | RNASE1, GTF3C4, POLRMT | RAB9A 3785/4885NPC1 219/4885PDE10A 3125/4885 |
| US-10426762-B2 | Inhibitors of hepatitis C virus polymerase | POLR2E, POLR2H, GTF3C3 | RAB9A 3932/4885NPC1 353/4885PDE10A 2692/4885 |
| US-20150182514-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | POLR2E, POLR2H, GTF3C3 | RAB9A 3932/4885NPC1 353/4885PDE10A 2692/4885 |
| US-20040224960-A1 | Pharmaceutical compositions and methods for their use | CYP3A5, CYP3A7, CYP3A43 | RAB9A 3252/4885NPC1 237/4885PDE10A 604/4885 |
| US-20170273962-A1 | Inhibitors of Hepatitis C Virus Polymerase | POLR2E, POLR2H, GTF3C3 | RAB9A 3932/4885NPC1 353/4885PDE10A 2692/4885 |
| US-20060189681-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | RNASE1, RNASEH1, NSUN3 | RAB9A 3188/4885NPC1 110/4885PDE10A 2955/4885 |
| US-20050176701-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | RNASE1, RNASEH1, NSUN3 | RAB9A 3188/4885NPC1 110/4885PDE10A 2955/4885 |
| US-20140322165-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | POLR2A, POLR2B, POLR2E | RAB9A 2683/4885NPC1 658/4885PDE10A 2932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.